187 related articles for article (PubMed ID: 22970733)
1. The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET).
Kanakis G; Kamp K; Tsiveriotis K; Feelders RA; Zormpala A; de Herder WW; Kaltsas G
Clin Endocrinol (Oxf); 2013 Jun; 78(6):950-6. PubMed ID: 22970733
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
Niederle MB; Hackl M; Kaserer K; Niederle B
Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.
Ito T; Sasano H; Tanaka M; Osamura RY; Sasaki I; Kimura W; Takano K; Obara T; Ishibashi M; Nakao K; Doi R; Shimatsu A; Nishida T; Komoto I; Hirata Y; Nakamura K; Igarashi H; Jensen RT; Wiedenmann B; Imamura M
J Gastroenterol; 2010 Feb; 45(2):234-43. PubMed ID: 20058030
[TBL] [Abstract][Full Text] [Related]
6. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach.
Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB
Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
8. Pathological characteristics and clinical specifications in gastroenteropancreatic neuroendocrine tumors: a study of 68 cases.
Stoica-Mustafa E; Pechianu C; Iorgescu A; Hortopan M; Dima SO; Tomulescu V; Dumitraşcu T; Ungureanu C; Andronesi D; Popescu I; Herlea V
Rom J Morphol Embryol; 2012; 53(2):351-5. PubMed ID: 22732805
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
[TBL] [Abstract][Full Text] [Related]
10. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
11. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis.
Chan DT; Luk AO; So WY; Kong AP; Chow FC; Ma RC; Lo AW
BMC Endocr Disord; 2016 Feb; 16():12. PubMed ID: 26911576
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
14. [Incidence, pathology and clinical course and symptoms of neuroendocrine gastrointestinal tumours].
Federspiel BH; Hansen CP; Vainer B; Hasselby JP; Bardram L; Knigge U
Ugeskr Laeger; 2010 Oct; 172(43):2946-50. PubMed ID: 21040672
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.
Ito T; Igarashi H; Nakamura K; Sasano H; Okusaka T; Takano K; Komoto I; Tanaka M; Imamura M; Jensen RT; Takayanagi R; Shimatsu A
J Gastroenterol; 2015 Jan; 50(1):58-64. PubMed ID: 24499825
[TBL] [Abstract][Full Text] [Related]
16. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
17. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.
Schimmack S; Svejda B; Lawrence B; Kidd M; Modlin IM
Langenbecks Arch Surg; 2011 Mar; 396(3):273-98. PubMed ID: 21274559
[TBL] [Abstract][Full Text] [Related]
18. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
19. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
[TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic endocrine tumors.
Meeker A; Heaphy C
Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
